Novo Nordisk stock ended 2021 at 56 and nearly tripled over the next three years. Wegovy became a blockbuster drug in 2023, shooting from $885 million in 2022 sales to almost $4.57 billion.

Novo Nordisk shares closed down 0.3% at $73.77 on Friday, but rose 0.7% to $74.26 in after-hours trading. The stock has declined 15.7% so far in 2025.

June 26 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Under the deal ...

Hims & Hers Health Inc.’s stock booked record losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth ...